Bausch + Lomb Corporation (S2L) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

S2L Analyst Ratings

Moderate Buy

5 Buy

5 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Bausch

+ Lomb Corporation

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

S2L Stock 12 Month Forecast

Average Price Target

€17.84

▲(23.03% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Bausch + Lomb Corporation in the last 3 months. The average price target is €17.84 with a high forecast of €21.17 and a low forecast of €14.12. The average price target represents a 23.03% change from the last price of €14.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","22":"€22","13.75":"€13.75","16.5":"€16.5","19.25":"€19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.1727964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.840041411111113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.1151976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,13.75,16.5,19.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.8,15.290215107692308,15.780430215384616,16.270645323076923,16.76086043076923,17.25107553846154,17.741290646153846,18.231505753846154,18.72172086153846,19.21193596923077,19.702151076923077,20.192366184615384,20.68258129230769,{"y":21.1727964,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.8,15.033849339316241,15.26769867863248,15.50154801794872,15.735397357264958,15.969246696581198,16.20309603589744,16.436945375213675,16.670794714529915,16.904644053846155,17.138493393162396,17.372342732478632,17.606192071794872,{"y":17.840041411111113,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.8,14.747322892307693,14.694645784615386,14.641968676923078,14.58929156923077,14.536614461538463,14.483937353846155,14.431260246153846,14.378583138461538,14.32590603076923,14.273228923076923,14.220551815384615,14.167874707692308,{"y":14.1151976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€21.17

Average Price Target€17.84

Lowest Price Target€14.12

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

€15.88

Hold

9.51%

Upside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Longeveron (NASDAQ: LGVN)

Daniel Clark

Leerink Partners

€21.17

Buy

46.02%

Upside

Initiated

09/09/26

Leerink bullish on Bausch + Lomb, initiates with an OutperformLeerink bullish on Bausch + Lomb, initiates with an Outperform

Yi Chen

H.C. Wainwright

€18.53

Buy

27.77%

Upside

Reiterated

08/28/26

Yi Chen Reiterates Buy on Bausch + Lomb, Citing Emerging Ophthalmology Pipeline and Maintaining $21 Price Target

Thomas Stephan

Stifel Nicolaus

€14.12

Hold

-2.65%

Downside

Reiterated

08/25/26

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Joanne Wuensch

Citi

€18.53

Buy

27.77%

Upside

Reiterated

08/13/26

Citi Sticks to Its Buy Rating for Bausch + Lomb Corporation (BLCO)

Vijay Kumar

Evercore ISI

€15

Hold

3.43%

Upside

Reiterated

07/30/26

Evercore ISI Remains a Hold on Bausch + Lomb Corporation (BLCO)

Douglas Miehm

RBC Capital

€18.53

Buy

27.77%

Upside

Reiterated

07/30/26

RBC Capital Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)

Travis Steed

Bank of America Securities

―

Sell

―

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Bausch + Lomb Corporation (NYSE: BLCO) and Pharming Group (NASDAQ: PHAR)

Patrick Wood

UBS

€18.53→€20.29

Buy

39.94%

Upside

Initiated

07/30/26

Bausch + Lomb initiated with a Buy at UBSBausch + Lomb initiated with a Buy at UBS

David Saxon

Needham

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Bausch + Lomb Corporation (NYSE: BLCO) and Curis (NASDAQ: CRIS)

David Roman

Goldman Sachs

€18.53

Hold

27.77%

Upside

Reiterated

07/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Pito Chickering

Deutsche Bank

€15.88→€14.12

Hold

-2.65%

Downside

Reiterated

04/30/26

Bausch + Lomb price target lowered to $16 from $18 at Deutsche BankBausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

Matt Miksic

Barclays

€17.64

Hold

21.68%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Align Tech (NASDAQ: ALGN) and Bausch + Lomb Corporation (NYSE: BLCO)

Robbie Marcus

J.P. Morgan

€11.47→€14.12

Hold

-2.65%

Downside

Reiterated

10/30/25

Bausch + Lomb price target raised to $16 from $13 at JPMorganBausch + Lomb price target raised to $16 from $13 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

€15.88

Hold

9.51%

Upside

Reiterated

09/18/26

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Longeveron (NASDAQ: LGVN)

Daniel Clark

Leerink Partners

€21.17

Buy

46.02%

Upside

Initiated

09/09/26

Leerink bullish on Bausch + Lomb, initiates with an OutperformLeerink bullish on Bausch + Lomb, initiates with an Outperform

Yi Chen

H.C. Wainwright

€18.53

Buy

27.77%

Upside

Reiterated

08/28/26

Yi Chen Reiterates Buy on Bausch + Lomb, Citing Emerging Ophthalmology Pipeline and Maintaining $21 Price Target

Thomas Stephan

Stifel Nicolaus

€14.12

Hold

-2.65%

Downside

Reiterated

08/25/26

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Joanne Wuensch

Citi

€18.53

Buy

27.77%

Upside

Reiterated

08/13/26

Citi Sticks to Its Buy Rating for Bausch + Lomb Corporation (BLCO)

Vijay Kumar

Evercore ISI

€15

Hold

3.43%

Upside

Reiterated

07/30/26

Evercore ISI Remains a Hold on Bausch + Lomb Corporation (BLCO)

Douglas Miehm

RBC Capital

€18.53

Buy

27.77%

Upside

Reiterated

07/30/26

RBC Capital Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)

Travis Steed

Bank of America Securities

―

Sell

―

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Bausch + Lomb Corporation (NYSE: BLCO) and Pharming Group (NASDAQ: PHAR)

Patrick Wood

UBS

€18.53→€20.29

Buy

39.94%

Upside

Initiated

07/30/26

Bausch + Lomb initiated with a Buy at UBSBausch + Lomb initiated with a Buy at UBS

David Saxon

Needham

―

Hold

―

Reiterated

07/29/26

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Bausch + Lomb Corporation (NYSE: BLCO) and Curis (NASDAQ: CRIS)

David Roman

Goldman Sachs

€18.53

Hold

27.77%

Upside

Reiterated

07/14/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Pito Chickering

Deutsche Bank

€15.88→€14.12

Hold

-2.65%

Downside

Reiterated

04/30/26

Bausch + Lomb price target lowered to $16 from $18 at Deutsche BankBausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

Matt Miksic

Barclays

€17.64

Hold

21.68%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Align Tech (NASDAQ: ALGN) and Bausch + Lomb Corporation (NYSE: BLCO)

Robbie Marcus

J.P. Morgan

€11.47→€14.12

Hold

-2.65%

Downside

Reiterated

10/30/25

Bausch + Lomb price target raised to $16 from $13 at JPMorganBausch + Lomb price target raised to $16 from $13 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

DFTXDefinium Therapeutics

OVIDOvid Therapeutics

ACHVAchieve Life Sciences

WSTWest Pharmaceutical Services

OMCLOmnicell

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bausch + Lomb Corporation

3 Months

Douglas MiehmRBC Capital

Success Rate

17/29 ratings generated profit

Average Return

+1.96%

Copying Douglas Miehm's trades and holding each position for 3 Months would result in 58.62% of your transactions generating a profit, with an average return of +1.96% per trade.

1 Year

Douglas MiehmRBC Capital

Success Rate

18/29 ratings generated profit

Average Return

+4.53%

Copying Douglas Miehm's trades and holding each position for 1 Year would result in 62.07% of your transactions generating a profit, with an average return of +4.53% per trade.

2 Years

Yi ChenH.C. Wainwright

Success Rate

9/14 ratings generated profit

Average Return

+6.29%

Copying Yi Chen's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +6.29% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

S2L Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, S2L has received 4 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. S2L average Analyst price target in the past 3 months is 17.84.

Each month's total comprises the sum of three months' worth of ratings.

S2L Financial Forecast

S2L Earnings Forecast

Next quarter’s earnings estimate for S2L is €0.19 with a range of €0.15 to €0.23. The previous quarter’s EPS was €0.13. S2L beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year S2L has Performed in-line its overall industry.

S2L Sales Forecast

Next quarter’s sales forecast for S2L is €1.22B with a range of €1.21B to €1.23B. The previous quarter’s sales results were €1.24B. S2L beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year S2L has Performed in-line its overall industry.

S2L Stock Forecast FAQ

What is DE:S2L’s average 12-month price target, according to analysts?

Based on analyst ratings, Bausch + Lomb Corporation’s 12-month average price target is 17.84.

What is DE:S2L’s upside potential, based on the analysts’ average price target?

Bausch + Lomb Corporation has 23.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bausch + Lomb Corporation a Buy, Sell or Hold?

Bausch + Lomb Corporation has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 5 hold ratings and 1 sell ratings.

What is Bausch + Lomb Corporation’s share price target?

The average share price target for Bausch + Lomb Corporation is 17.84. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €21.17 ,and the lowest forecast is €14.12. The average share price target represents 23.03% Increase from the current price of €14.5.

What do analysts say about Bausch + Lomb Corporation?

Bausch + Lomb Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Bausch + Lomb Corporation?

To buy shares of DE:S2L, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bausch + Lomb Corporation (S2L) Stock Forecast & Price Target

S2L Analyst Ratings

S2L Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bausch + Lomb Corporation

S2L Analyst Recommendation Trends

S2L Financial Forecast

S2L Earnings Forecast

S2L Sales Forecast

S2L Stock Forecast FAQ

Detailed List of Analyst Forecasts